BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 11602414)

  • 1. Severe infections after allogeneic peripheral blood stem cell transplantation: a matched-pair comparison of unmanipulated and CD34+ cell-selected transplantation.
    Martino R; Rovira M; Carreras E; Solano C; Jorge S; De La Rubia J; Caballero MD; de Oteyza JP; Zuazu J; Moraleda JM; Ojeda E; Ferrá C; Serrano D; De La Cámara R; Urbano-Ispízua A; Brunet S;
    Haematologica; 2001 Oct; 86(10):1075-86. PubMed ID: 11602414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced-intensity conditioning reduces the risk of severe infections after allogeneic peripheral blood stem cell transplantation.
    Martino R; Caballero MD; Canals C; San Miguel J; Sierra J; Rovira M; Solano C; Bargay J; Pérez-Simon J; León A; Sarrá J; Brunet S; de la Cámara R;
    Bone Marrow Transplant; 2001 Aug; 28(4):341-7. PubMed ID: 11571505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogeneic transplantation of G-CSF mobilized peripheral blood stem cells from unrelated donors: a retrospective analysis.
    Bornhäuser M; Theuser C; Soucek S; Hölig K; Klingebiel T; Blau W; Fauser A; Runde V; Schwinger W; Rutt C; Ehninger G
    Haematologica; 2000 Aug; 85(8):839-47. PubMed ID: 10942931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe infections after unrelated donor allogeneic hematopoietic stem cell transplantation in adults: comparison of cord blood transplantation with peripheral blood and bone marrow transplantation.
    Parody R; Martino R; Rovira M; Vazquez L; Vázquez MJ; de la Cámara R; Blazquez C; Fernández-Avilés F; Carreras E; Salavert M; Jarque I; Martín C; Martínez F; López J; Torres A; Sierra J; Sanz GF;
    Biol Blood Marrow Transplant; 2006 Jul; 12(7):734-48. PubMed ID: 16785063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allogeneic peripheral blood stem cell transplantation with CD34+-cell selection and delayed T-cell add-back in adults. Results of a single center pilot study.
    Martino R; Martín-Henao G; Sureda A; Altés A; Canals C; Brunet S; Sierra J
    Haematologica; 2000 Nov; 85(11):1165-71. PubMed ID: 11064469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative lymphocyte subset reconstitution after allogeneic hematopoietic transplantation from matched related donors with CD34+ selected PBPC grafts unselected PBPC grafts or BM grafts.
    Behringer D; Bertz H; Schmoor C; Berger C; Dwenger A; Finke J
    Bone Marrow Transplant; 1999 Aug; 24(3):295-302. PubMed ID: 10455369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized trial of high dose polyvalent intravenous immunoglobulin (HDIgG) vs. Cytomegalovirus (CMV) hyperimmune IgG in allogeneic hemopoietic stem cell transplants (HSCT).
    Zikos P; Van Lint MT; Lamparelli T; Gualandi F; Occhini D; Mordini N; Berisso G; Bregante S; Bacigalupo A
    Haematologica; 1998 Feb; 83(2):132-7. PubMed ID: 9549924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre-emptive immunotherapy with CD8-depleted donor lymphocytes after CD34-selected allogeneic peripheral blood stem cell transplantation.
    Baron F; Siquet J; Schaaf-Lafontaine N; Baudoux E; Hermanne JP; Fillet G; Beguin Y
    Haematologica; 2002 Jan; 87(1):78-88. PubMed ID: 11801468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
    George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
    Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk for cytomegalovirus infection following reduced intensity allogeneic stem cell transplantation.
    Nachbaur D; Larcher C; Kircher B; Eibl G; Nussbaumer W; Gunsilius E; Haun M; Grünewald K; Gastl G
    Ann Hematol; 2003 Oct; 82(10):621-7. PubMed ID: 12920570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced risk of persisting cytomegalovirus pp65 antigenemia and cytomegalovirus interstitial pneumonia following allogeneic PBSCT.
    Trenschel R; Ross S; Hüsing J; Ottinger H; Elmaagacli A; Roggendorf M; Schaefer UW; Runde V
    Bone Marrow Transplant; 2000 Mar; 25(6):665-72. PubMed ID: 10734302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transplantation with higher dose of natural killer cells associated with better outcomes in terms of non-relapse mortality and infectious events after allogeneic peripheral blood stem cell transplantation from HLA-matched sibling donors.
    Kim DH; Sohn SK; Lee NY; Baek JH; Kim JG; Won DI; Suh JS; Lee KB; Shin IH
    Eur J Haematol; 2005 Oct; 75(4):299-308. PubMed ID: 16146536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Boost of CD34+-selected peripheral blood cells without further conditioning in patients with poor graft function following allogeneic stem cell transplantation.
    Larocca A; Piaggio G; Podestà M; Pitto A; Bruno B; Di Grazia C; Gualandi F; Occhini D; Raiola AM; Dominietto A; Bregante S; Lamparelli T; Tedone E; Oneto R; Frassoni F; Van Lint MT; Pogliani E; Bacigalupo A
    Haematologica; 2006 Jul; 91(7):935-40. PubMed ID: 16818281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infections after CD34-selected or unmanipulated autologous hematopoietic stem cell transplantation.
    Frère P; Pereira M; Fillet G; Beguin Y
    Eur J Haematol; 2006 Feb; 76(2):102-8. PubMed ID: 16405430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytomegalovirus infection and disease after reduced intensity conditioning allogeneic stem cell transplantation: single-centre experience.
    Piñana JL; Martino R; Barba P; Margall N; Roig MC; Valcárcel D; Sierra J; Rabella N
    Bone Marrow Transplant; 2010 Mar; 45(3):534-42. PubMed ID: 19668235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for late cytomegalovirus infection after allogeneic stem cell transplantation using HLA-matched sibling donor: donor lymphocyte infusion and previous history of early CMV infection.
    Kim DH; Kim JG; Lee NY; Sung WJ; Sohn SK; Suh JS; Lee KS; Lee KB
    Bone Marrow Transplant; 2004 Jul; 34(1):21-7. PubMed ID: 15133483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Marked reduction in the incidence of hepatic veno-occlusive disease after allogeneic hematopoietic stem cell transplantation with CD34(+) positive selection.
    Moscardó F; Sanz GF; de La Rubia J; Jiménez C; Saavedra S; Regadera A; Andreu R; García I; Plumé G; Martínez J; Martín G; Jarque I; Sanz MA
    Bone Marrow Transplant; 2001 May; 27(9):983-8. PubMed ID: 11436110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Higher risk of cytomegalovirus and aspergillus infections in recipients of T cell-depleted unrelated bone marrow: analysis of infectious complications in patients treated with T cell depletion versus immunosuppressive therapy to prevent graft-versus-host disease.
    van Burik JA; Carter SL; Freifeld AG; High KP; Godder KT; Papanicolaou GA; Mendizabal AM; Wagner JE; Yanovich S; Kernan NA
    Biol Blood Marrow Transplant; 2007 Dec; 13(12):1487-98. PubMed ID: 18022579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of infection-related mortality after allogeneic PBSCT from HLA-identical siblings: longitudinal analysis from 1994 to 2008 at a single institution.
    Martino R; Kerguelen A; Valcárcel D; Sureda A; Fachini L; Piñana JL; Briones J; Delgado J; Brunet S; Sierra J
    Bone Marrow Transplant; 2011 May; 46(5):690-701. PubMed ID: 20818448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.